News
IMA
6.91
+0.88%
0.06
Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26
TipRanks · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/12/26
TipRanks · 2d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/11/26
TipRanks · 3d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/10/26
TipRanks · 4d ago
ImageneBio appoints Ben Porter-Brown as Chief Medical Officer
TipRanks · 4d ago
*ImageneBio Appoints Ben Porter-Brown as Chief Medical Officer >IMA
Dow Jones · 4d ago
ImageneBio Names Dr. Ben Porter-Brown as Chief Medical Officer
Reuters · 4d ago
Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Dow Jones · 4d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at IMA last week (0202-0206)?
Weekly Report · 5d ago
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/6/26
TipRanks · 02/06 16:02
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/4/26
TipRanks · 02/04 13:23
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/3/26
TipRanks · 02/03 11:58
Vanguard Total Stock Market ETF (VTI) Daily Update—2/2/26
TipRanks · 02/02 12:39
Weekly Report: what happened at IMA last week (0126-0130)?
Weekly Report · 02/02 10:22
Vanguard VTI Daily Snapshot — Jan. 30
TipRanks · 01/30 13:28
Vanguard Total Stock Market ETF (VTI) Daily Update—1/29/26
TipRanks · 01/29 13:16
Vanguard Total Stock Market ETF (VTI) Daily Update—1/28/26
TipRanks · 01/28 13:28
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/27/26
TipRanks · 01/27 13:57
VTI ETF Sees $1B Inflows — Are Investors Turning More Bullish?
TipRanks · 01/26 11:50
More
Webull provides a variety of real-time IMA stock news. You can receive the latest news about ImageneBio through multiple platforms. This information may help you make smarter investment decisions.
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.